Skip to main content
Clinical Trials/NCT01988805
NCT01988805
Withdrawn
Not Applicable

Immunological Characterization of Blood and Inflammasome Gene Segment Polymorphism Analysis of Normal Healthy Individuals

Ohio State University1 site in 1 countryFebruary 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Healthy Individuals
Sponsor
Ohio State University
Locations
1
Primary Endpoint
analyze their ability to respond to exogenous challenges by changing the production of proteins, the expression of genes and their ability to migrate and ingest materials
Status
Withdrawn
Last Updated
11 years ago

Overview

Brief Summary

This study is intended to collect blood from healthy individuals to investigate whether variations in immune-related (inflammasome) genes affect how the immune cells found in the blood can help fight infections and prevent diseases.

Registry
clinicaltrials.gov
Start Date
February 2013
End Date
February 2014
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mark D. Wewers, MD

Associate Director, Pulmonary Research

Ohio State University

Eligibility Criteria

Inclusion Criteria

  • Healthy with no chronic or acute illnesses, or taking medication which in the opinion of the PI would impact the analyses being conducted.
  • At least 18 years or older.
  • Are capable of reading, understanding and providing written informed consent.

Exclusion Criteria

  • Non-English speaking.
  • Individuals under 18 years old.
  • Woman who believe they are or may be pregnant. (Based on self reporting. Pregnancy testing will not be conducted for the purposes of this study)
  • Individuals experiencing acute or chronic illnesses which in the opinion of the PI would impact the analyses being conducted.
  • Currently taking prescription or over the counter medication which in the opinion of the PI would impact the analyses being conducted.
  • Individual has donated blood more than twice in the last week or the amount to be drawn will exceed the maximum allowance in the last 8 weeks.

Outcomes

Primary Outcomes

analyze their ability to respond to exogenous challenges by changing the production of proteins, the expression of genes and their ability to migrate and ingest materials

Time Frame: one visit

Our intent is to collect these cells, divide them into subtypes such as monocytes, lymphocytes and neutrophils and then to analyze their ability to respond to exogenous challenges by changing the production of proteins, the expression of genes and their ability to migrate and ingest materials. We additionally will be interested in examining the cell components that may be released from these cells during various in vitro challenges.

Study Sites (1)

Loading locations...

Similar Trials